FAVO Capital Appoints Healthcare Executive Dr. Wael Barsoum to Board of Directors

FAVO Capital (OTC: FAVO) has appointed Dr. Wael Barsoum to its board of directors as an independent director, bringing significant healthcare leadership experience to the diversified financial company. Barsoum previously served as president and CEO of Cleveland Clinic Florida and currently holds the position of president and chief transformation officer at Healthcare Outcomes Performance Company. His decades of experience in healthcare innovation, governance, and organizational growth positions him to contribute valuable insights to FAVO Capital's strategic direction.

Shaun Quin, president of FAVO Capital, emphasized the strategic importance of this appointment, stating that Barsoum's addition reflects the company's commitment to building a board with the independence, depth, and experience necessary to guide FAVO's next chapter of growth. This move signals FAVO's intention to strengthen its corporate governance while potentially exploring synergies between healthcare innovation and financial services.

FAVO Capital operates as a diversified financial company with two primary business segments: financial services and selective real assets. Through its financial services division, the company provides alternative, revenue-based funding solutions to small and mid-sized businesses across the United States. Since its inception, FAVO has supported more than 10,000 businesses through the purchase of future receipts, establishing itself as a significant player in the alternative lending space.

Complementing its lending platform, FAVO is building a portfolio of selective real assets that strengthen its balance sheet and broaden its collateral base. The company maintains operations in Florida, New York, and the Dominican Republic, with headquarters located in Fort Lauderdale, Florida. FAVO Capital's commitment to financial transparency, sustainable growth, and long-term value creation for shareholders underpins its strategic initiatives.

The appointment of a healthcare executive to the board of a financial services company may indicate FAVO's interest in exploring healthcare financing opportunities or applying healthcare innovation principles to financial services. Barsoum's background in transformation and performance improvement could bring valuable perspectives to FAVO's operational efficiency and growth strategies. Investors can access the latest news and updates relating to FAVO in the company's newsroom at https://nnw.fm/FAVO.

This board appointment comes at a time when corporate governance and independent oversight are increasingly important to investors and regulators. The addition of an independent director with Barsoum's credentials enhances FAVO's corporate governance profile and may improve investor confidence in the company's strategic direction. The full press release detailing this appointment is available at https://nnw.fm/gLEvl.

The intersection of healthcare expertise and financial services represents a potentially significant development for small and mid-sized businesses seeking alternative funding solutions. Barsoum's experience in healthcare innovation could inform FAVO's approach to serving businesses in the healthcare sector or applying healthcare industry best practices to financial operations. This appointment demonstrates FAVO's commitment to bringing diverse industry perspectives to its boardroom discussions and strategic planning processes.